Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report

RATIONALE: Keytruda (pembrolizumab) is an inhibitor of programmed cell death receptor-1 (PD-1), which was approved to treat advanced melanoma and nonsmall cell lung cancer patients who do not respond to other treatment. However, its efficacy and security in the treatment of advanced liver cancer is...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhenping, Lai, Lingling, Li, Ming, Zhang, Lunli, Zhang, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758274/
https://www.ncbi.nlm.nih.gov/pubmed/29390572
http://dx.doi.org/10.1097/MD.0000000000009431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758274/
https://www.ncbi.nlm.nih.gov/pubmed/29390572
http://dx.doi.org/10.1097/MD.0000000000009431

Ejemplares similares